UK Markets closed

Achiko AG (ACHKF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.13000.0000 (0.00%)
At close: 09:30AM EDT
Sign in to post a message.
  • L
    Logan Roy
    Who’s in this still?
  • A
    Adrian
    Flying now financing in play
  • C
    Covid
    "Achiko (OTCQB: ACHKF) is pleased to announce that the Company has signed an agreement with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta for the delivery of aptamer-based diagnostics first to its Jakarta branch of over 4 million members."

    "What does this mean? NU is the largest Islamic organization in the world with over 90 million registered members, several hundred hospitals and clinics, in a country of 270 million people over 6,000 islands."

    "The right test that empowers people to be able to manage their personal response to Covid in a fast growing country like Indonesia is a big thing. The deal also includes Indofarma (who has ordered the production of the first 1m test kits as inventory). We expect to be doing 5,000,000 tests per month in 3-6 months from now, and as much as 10,000,000 tests per month within 12 months (expected retail price is USD$3.50 a test). It is a big country."

    "Why this matters? Because Covid isn’t over. Vaccines and Boosters wane and it’s mutating. PCR testing is being dropped everywhere for Antigen based Rapid testing. And Antigen based Rapid tests are having trouble picking up Omicron. Instead, we use DNA Aptamers and target what appears to be the non mutating part of the S1 Spike. Through differentiated chemistry we appear to be correctly classifying negatives and positives compared to PCR CT cases at 33 (most rapid tests start to fall off at 25)."

    "What's next from here? The deal covers more than just Covid testing. The advantages by using Aptamers rather than Antigens opens the door to a broad range of diagnostics across a wide range of biomarkers. Its possible we'll do a lot more than 10m tests a month in indo and this deal is just the first of many there. And we're about to launch in a pile of other countries. Very excited about that."

    "Special thanks? Grateful to a fantastic team in Indonesia. Supported by friends in Taiwan and other parts of Asia. And in Spain. And to all our partners in Swiss who've been supporting the company." - Steven Goh, Achiko CEO

    #achiko #indofarma #NU #Indonesia #AptameX #Covid19 #AptameX #covidtesting #covidsalivatest

    https://www.achiko.com/2022/04/20/achiko-ag-signs-major-marketing-and-sales-agreement-with-the-worlds-largest-islamic-association-for-its-aptamex-covid-19-rapid-test
  • S
    Stiffmeister
    Move !
  • S
    SwissCheese
    Well, I spoke too qui kly...News this morning. How do you interprete it?
    https://www.achiko.com/2020/09/28/achiko-ag-annonce-ses-resultats-semestriels-au-30-juin-2020/?lang=fr
  • N
    Nick
    It seems Achiko is too late with their test. Or what do you think? Interested in your opinion
  • S
    SwissCheese
    Yeah you re right, 0.55 on the Six page with a total volume of already 224k which is big for Achiko... any info on what is happening?
  • f
    flo
    whats going on??
  • d
    david
    Must be some news coming out soon , they seemed to market it weekly in 2020 . Hopefully it’s testing news or app news ..
  • S
    Stiffmeister
    Something happening ?
  • N
    Nick
    Where are you stiffyboy?
  • L
    Logan Roy
    My high risk high reward pick of 2022!
  • A
    Albert
    Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution
    - 2021 was a pivotal year for Achiko, marked by seminal developments and approvals
    - With AptameX(TM), Achiko launched an innovative DNA aptamer saliva-based rapid test for Covid-19 as an affordable and effective diagnostic for frequent mass testing
    - Second-generation of AptameX received full approval in Indonesia for five years
    - Focus on completing CE Mark and commercialization beyond Indonesia in 2022
    - In 2022, Achiko looks to further the Company's growth, proceeding to AptameX trials in other countries, completing its CE Mark registration to bring AptameX to other parts of Asia, the Middle East and northern Africa (MENA), and eastern Europe
  • L
    Logan Roy
    Anyone still in this too?
  • A
    Albert
    a higher volume today.

    achiko's shares have been tradable on otcqb since today. 2022 could be the breakthrough year for achiko when the CE audit takes place.

    achiko expects CE marking in q1 2022, after which the product will be approved worldwide
  • C
    Covid
    These two additions to the executive are significant:

    Achiko AG appoints biotechnology research scientist and entrepreneur Dr. Morris S. Berrie to the position of President, and business leader in the life science industry Richard Lingard to the position of SVP Commercialization.

    Dr. Berrie brings over 20 years of scientific, business and financial experience in the biotechnology and healthcare industries. He served as Co-Founder/Chairman of TTS Global Initiative which globally facilitates deal flow in the early stage/SME biotech sector and was a partner of several EU Horizon 2020 multi-million Euro projects aiding the European SME sector. He is also Director of Tech Investor Ltd. which consults and advises government organizations, regions, and companies throughout the biotech sector on the commercialization of science, including business development and capital raising.

    Prior, Dr. Berrie was the Chief Executive Officer and Editor-in-Chief of the Biotechnology Investment Today Group where he worked with numerous prestigious clients from both the healthcare and the financial industries, including the U.S. National Institutes of Health (NIH), Pfizer, GSK, Needham & Co, Orbimed, TVM, JPMorgan and many more.

    Mr. Lingard is an accomplished business leader with over 25 years’ experience in the life science industry. He has a chemistry background and has worked with a range of multinational corporations, contract research organisations (CROs) and start-up companies.

    Previously, he was CEO of Adroit-DI, where he developed a software platform to unify research. Mr. Lingard was Head of Europe, Middle East, India and Russia for Taconic Biosciences, creating a partner ecosystem and structuring his division to assist with the sale of Taconic to H.I.G. Capital.

    Mr. Lingard was SVP Global Commercial Operations for Dotmatics, a global software solution and service provider, where he doubled his international team of PhD scientists, sales, and marketing to triple the business turnover in three years. Prior to that, he led business development, sales, commercialization and partnership positions at Clarivate Analytics, Thermo Fisher, Charles River, Biovia, Exelixis and Merck & Co Inc.
  • A
    Albert
    This company is massively undervalued
  • H
    Hans
    Is this over here? No positive news, only downtrend. What are they doing? What about gumnuts?